Clinically, low SETD2 is highly related to reduced VHL in mRNA and protein levels (TCGA-KIRC database, Supplementary Fig. 4f, g), suggesting an association between SETD2 loss and decreased VHL expression in the context of ccRCC. Here, SETD2 is linked to nonpapillary renal cell carcinoma.